Most solid organ transplant rejections occur in the one to five years of the transplant. Post-transplant monitoring and early detection of graft rejection are critical and crucial for patients. The old methods of testing graft rejection are invasive, less patient-friendly and unable to detect graft rejection early enough. Late detection of graft rejection causes significant damage to the transplanted organ, resulting in poor quality of life for the patient.
Trunome Liquid Biopsy is a revolutionary non-invasive diagnostic test that enables the early detection and monitoring of chronic diseases through a blood test. Being the first and entirely made-in-India technology platform in Asia, it is protected by patents * “ours” being a US patented technology* and is known for its high effectiveness and accuracy in monitoring organ health.
Trunome-Tx specializes in offering solutions for post-transplant organ health. An innovative diagnostic test called Trunome is a non-invasive method that helps detect early rejection of solid organ transplants through a blood test. This test can effectively monitor the health of transplanted solid organs such as the kidney, liver, heart, lungs, and pancreas. Trunome-Tx also provides specialised care solutions to support post-transplant recovery and long-term health.
Trunome Advantages
- Faster results with real-time detection
- Significantly reduces uncertainties
- More detailed & accurate information
- Detects ALL rejection types with a single blood draw
- Lowers the risk of missing an active rejection
- Offers precision & absolute quantification
- Utilizes advanced algorithms for improved performance
- Overcome challenges of sampling difficult-to-obtain tissue
- Facilitates easy repeatable samplings for longitudinal analysis
- Stable post-transplant patient
- High-risk post-transplant patient
- post-transplant patients with a history of allograft rejections
- Repeated post-transplant patient
- Pediatric post-transplant patients
